Similarly, our results regarding osteopontin agree with Stampanoni et al., who reported increased osteopontin levels in MS patients with active disease, implicating osteopontin in pathways linking immune activation to CNS injury [20]. The gene discussed is SPP1; the disease is myeloid sarcoma.